查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553690

药物杂质合成和分离服务的市场规模、份额和趋势分析报告：按服务、按杂质类型、按技术、按应用、按最终用途、按地区和细分趋势：2024-2030

Pharmaceutical Impurity Synthesis And Isolation Services Market Size, Share & Trends Analysis Report By Services, By Impurity Type, By Technique, By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

药物杂质合成和分离服务市场的成长和趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球医药杂质合成与分离服务市场规模预计将达到19.4亿美元，预测期内复合年增长率为8.03%。

药物杂质检测、定量和分析控制策略对于优化药品成品和原料药的安全性、纯度和品管至关重要。药品中的杂质可能来自多种来源，包括试剂、起始原料及其污染物、催化剂、中间体、溶剂、赋形剂及其污染物、降解产物。

药物配方日益复杂也促进了市场成长。随着生技药品、复杂学名药和新型药物输送系统的不断发展，杂质的性质变得更加多样化且难以识别。这种复杂性需要先进的分析技术和专家服务来进行准确的杂质分析。公司正在寻求专业服务来满足这些需求，从而推动对杂质合成和分离服务的需求。因此，上述因素正在促进市场成长。

此外，分析技术的持续进步进一步推动了对杂质合成和分离服务的需求。高分辨率质谱和先进层析法技术等更复杂方法的发展使得杂质的精确检测和表征成为可能。采用并整合这些最尖端科技的服务供应商可以轻鬆满足製药业不断增长的需求，进一步推动市场成长。

製药业合作研究和外包的成长趋势在市场动态中发挥重要作用。为了专注于核心竞争力并降低营运成本，製药公司越来越多地委託给专业服务供应商。这种外包趋势为服务供应商扩大服务范围并满足世界各地客户的需求创造了机会。因此，上述因素正在推动市场成长。

药物杂质合成和分离服务市场报告亮点

  • 从服务业来看，2023年，分离服务业占据市场主导地位，份额为39.41%。杂质分离是确保药品安全性和有效性的基本方面。监管机构需要全面的杂质谱，并且需要将这些物质从药品中有效分离。
  • 根据杂质类型，无机杂质细分市场将在 2023 年占据主导地位。技术进步在无机杂质领域的主导地位中发挥着重要作用。感应耦合电浆质谱 (ICP-MS) 和原子吸收光谱 (AAS) 等分析技术的创新极大地提高了高灵敏度和高精度检测和定量无机杂质的能力。
  • 按技术划分，层析法市场在 2023 年占据最大的收益占有率。药物配方日益复杂，推动了对先进层析法技术的需求。现代药物，包括生技药品、胜肽和复杂的学名药，通常含有复杂的混合物，需要适当的分离方法。
  • 按应用划分，商业製造领域在 2023 年占据最大收益占有率。全球药品市场的成长和全球药品生产设施的扩张正在推动该领域的成长。随着製药公司提高产能并进入新市场，对可靠的杂质分析服务的需求显着增加。
  • 根据最终用途，生物技术和製药公司部门在 2023 年占据最大的收益占有率。生物技术和製药公司对研发（R＆D）的大量投资正在促进该领域的成长。
  • 北美地区在 2023 年以 37.98% 的收益占有率占据市场主导地位。该地区的收益成长得益于大量的研发活动和政府措施。此外，製药公司和外包服务供应商的强大影响力也是推动市场成长的主要因素。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章 药物杂质合成与分离服务的变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/补充市场展望。
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 定价模式分析
  • 技术景观
  • 医药杂质合成与分离服务市场分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章药物杂质合成/分离服务市场：按服务分类的估计和趋势分析

  • 细分仪表板
  • 全球医药杂质合成分离服务市场、服务波动分析
  • 2018-2030年全球药物杂质合成与分离服务规模及趋势分析（分服务）
  • 合成服务
  • 分离服务
  • 分析服务

第五章药物杂质合成与分离服务市场：依杂质类型的估计和趋势分析

  • 细分仪表板
  • 全球药物杂质合成与分离服务市场、杂质类型波动分析
  • 2018-2030年全球药物杂质合成与分离服务规模及趋势分析（依杂质类型）
  • 无机杂质
  • 有机杂质
  • 残留溶剂

第六章药物杂质合成与分离服务市场：技术估算与趋势分析

  • 细分仪表板
  • 全球药物杂质合成与分离服务市场、技术变迁分析
  • 2018-2030年全球医药杂质合成与分离服务规模及趋势分析（分技术）
  • 层析法
  • 光谱学
  • 结晶
  • 连字符技术
  • 其他的

第七章药物杂质合成与分离服务市场：依应用估算与趋势分析

  • 细分仪表板
  • 全球药物杂质合成与分离服务市场、应用变迁分析
  • 2018-2030年全球药物杂质合成与分离服务规模及趋势分析（依应用）
  • 商业製造
    • 2018-2030 年市场估计与预测
  • 药物开发
    • 2018-2030 年市场估计与预测
  • 品管
    • 2018-2030 年市场估计与预测
  • 监理合规性
    • 2018-2030 年市场估计与预测

第八章药物杂质合成和分离服务市场：最终用途的估计和趋势分析

  • 细分仪表板
  • 全球药物杂质合成与分离服务市场最终用途变化分析；
  • 2018-2030年全球药物杂质合成和分离服务的规模和趋势分析（按最终用途）
  • 生物技术和製药公司
  • 受託研究机构（CRO）
  • 其他的

第九章药物杂质合成和分离服务市场：按服务、杂质类型、技术、应用和最终用途进行区域估计和趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第10章竞争格局

  • 公司分类
  • 2023 年企业市场分析
  • 公司简介
    • Eurofins Scientific
    • Charles River Laboratories
    • Wuxi AppTec
    • SGS Societe Generale de Surveillance SA.
    • Intertek Group Plc
    • Almac Group
    • Cambrex Corporation
    • Pharmaron
    • Laboratory Corporation of America Holdings
    • Syngene International Limited
    • PCI Pharma Services
    • Catalent Inc
    • Symeres
    • Piramal Pharma Solutions
    • Frontage Labs
    • Veeda Clinical Research
Product Code: GVR-4-68040-435-5

Pharmaceutical Impurity Synthesis And Isolation Services Market Growth & Trends:

The global pharmaceutical impurity synthesis and isolation services market size is expected to reach USD 1.94 billion by 2030, growing at a CAGR of 8.03% during the forecast period, according to a new report by Grand View Research, Inc.

Pharmaceutical impurity testing, quantification, and analytical control strategies are important in optimizing safety, purity, and quality control for finished drug products and drug substances. Pharmaceutical impurities can arise from several sources and include reagents, starting materials and their contaminants, catalysts, intermediates, solvents, excipients and their contaminants, and degradation products.

The growing complexity of pharmaceutical formulations is also contributing to market growth. With the increasing development of biologics, complex generics, and novel drug delivery systems, the nature of impurities has become more diverse and challenging to identify. This complexity necessitates advanced analytical techniques and expert services for accurate impurity profiling. Companies seek specialized services to handle these requirements, driving demand for impurity synthesis and isolation services. Thus, the aforementioned factors contribute to market growth.

Moreover, continuous technological advancements in analytical techniques further driving the demand for impurity synthesis and isolation services. The development of more sophisticated methods, such as high-resolution mass spectrometry and advanced chromatographic techniques, enables more precise detection and characterization of impurities. Service providers that adopt and integrate these cutting-edge technologies would easily meet the growing needs of the pharmaceutical industry, further driving growth in the market.

Growing collaboration and outsourcing trends in the pharmaceutical industry play a significant role in the market dynamics. Pharmaceutical companies are increasingly outsourcing impurity synthesis and isolation to specialized service providers to focus on their core competencies and reduce operational costs. This outsourcing trend creates opportunities for service providers to expand their offerings and cater to global clients. Thus, the aforementioned factors are driving the growth of the market.

Pharmaceutical Impurity Synthesis And Isolation Services Market Report Highlights:

  • Based on service, the isolation service segment dominated the market with a share of 39.41% in 2023. Isolation of impurities is a fundamental aspect of ensuring the safety and efficacy of pharmaceutical products. Regulatory agencies require comprehensive impurity profiles, which necessitate effectively isolating these substances from drug formulations.
  • Based on impurity type, the inorganic impurities segment dominated the market in 2023. Technological advancements have played a significant role in dominating the segment of inorganic impurities. Innovations in analytical techniques, such as Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and Atomic Absorption Spectroscopy (AAS), have greatly enhanced the ability to detect and quantify inorganic impurities with high sensitivity and accuracy.
  • Based on technique, the chromatography segment accounted for the largest revenue share in 2023. Increasing complexity of pharmaceutical formulations is driving the demand for advanced chromatographic techniques. Modern drugs, including biologics, peptides, and complex generics, often involve intricate mixtures that require proper separation methods.
  • Based on application, the commercial manufacturing segment accounted for the largest revenue share in 2023. Growing global pharmaceutical market and expanding pharmaceutical production facilities worldwide are contributing to the segment's growth. As pharmaceutical companies increase their production capacities and enter new markets, the need for reliable impurity analysis services grows significantly.
  • Based on end use, the biotech and pharmaceutical companies segment accounted for the largest revenue share in 2023. Biotech and pharmaceutical companies' significant investment in research and development (R&D) is contributing to the segment's growth.
  • North America dominated the market with a revenue share of 37.98% in 2023. The regional revenue growth is owing to high R&D activities and government initiatives. Moreover, strong presence of pharmaceutical companies and outsourcing service providers is another major factor expected to propel market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Service
    • 1.2.2. Impurity Type
    • 1.2.3. Technique
    • 1.2.4. Application
    • 1.2.5. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Pharmaceutical Impurity Synthesis and Isolation Services Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Stringent Regulatory Landscape
      • 3.2.1.2. Increasing Pharmaceutical R&D Spending
      • 3.2.1.3. Technological Advancement in Analytical Testing
      • 3.2.1.4. Growing Outsourcing Trend in the Market
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of Skilled workforce
      • 3.2.2.2. Contractual Obligation
  • 3.3. Pricing Model Analysis
  • 3.4. Technology Landscape
  • 3.5. Pharmaceutical Impurity Synthesis and Isolation Services Market Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Pharmaceutical Impurity Synthesis And Isolation Services Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Pharmaceutical Impurity Synthesis and Isolation Services Market; Service Movement Analysis
  • 4.3. Global Pharmaceutical Impurity Synthesis and Isolation Services Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 4.4. Synthesis Services
    • 4.4.1. Synthesis services market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Isolation Services
    • 4.5.1. Isolation services market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Analytical Services
    • 4.6.1. Analytical services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmaceutical Impurity Synthesis And Isolation Services Market: Impurity Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Pharmaceutical Impurity Synthesis and Isolation Services Market; Impurity Type Movement Analysis
  • 5.3. Global Pharmaceutical Impurity Synthesis and Isolation Services Size & Trend Analysis, by Impurity Type, 2018 to 2030 (USD Million)
  • 5.4. Inorganic Impurities
    • 5.4.1. Inorganic impurities market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Organic impurities
    • 5.5.1. Organic impurities market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Residual Solvents
    • 5.6.1. Residual solvents market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmaceutical Impurity Synthesis And Isolation Services Market: Technique Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Pharmaceutical Impurity Synthesis and Isolation Services Market; Technique Movement Analysis
  • 6.3. Global Pharmaceutical Impurity Synthesis and Isolation Services Size & Trend Analysis, by Technique, 2018 to 2030 (USD Million)
  • 6.4. Chromatography
    • 6.4.1. Chromatography market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. HPLC
      • 6.4.2.1. HPLC market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Gas Chromatography
      • 6.4.3.1. Gas chromatography market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Preparative Chromatography
      • 6.4.4.1. Preparative chromatography market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Others
      • 6.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Spectroscopy
    • 6.5.1. Spectroscopy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Mass Spectroscopy
      • 6.5.2.1. Mass spectroscopy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Nuclear Magnetic Resonance (NMR) Spectroscopy
      • 6.5.3.1. Nuclear Magnetic Resonance (NMR) spectroscopy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Others
      • 6.5.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Crystallization
    • 6.6.1. Crystallization market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Hyphenated Techniques
    • 6.7.1. Hyphenated techniques market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Pharmaceutical Impurity Synthesis And Isolation Services Market: Application Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Pharmaceutical Impurity Synthesis and Isolation Services Market; Application Movement Analysis
  • 7.3. Global Pharmaceutical Impurity Synthesis and Isolation Services Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 7.4. Commercial Manufacturing
    • 7.4.1. Commercial manufacturing market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Drug Development
    • 7.5.1. Drug development market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Quality Control
    • 7.6.1. Quality control market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Regulatory Compliance
    • 7.7.1. Regulatory compliance market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Pharmaceutical Impurity Synthesis And Isolation Services Market: End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Pharmaceutical Impurity Synthesis and Isolation Services Market; End Use Movement Analysis
  • 8.3. Global Pharmaceutical Impurity Synthesis and Isolation Services Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 8.4. Biotech & Pharmaceutical Companies
    • 8.4.1. Biotech & pharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Contract Research Organizations (CRO)
    • 8.5.1. Contract Research Organizations (CRO) market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Others
    • 8.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Pharmaceutical Impurity Synthesis And Isolation Services Market: Regional Estimates & Trend Analysis by Service, Impurity Type, Technique, Application, End Use

  • 9.1. Regional Market Share Analysis, 2023 & 2030
  • 9.2. Regional Market Dashboard
  • 9.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 9.4. North America
    • 9.4.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 9.4.2. U.S.
      • 9.4.2.1. Key country dynamics
      • 9.4.2.2. Competitive scenario
      • 9.4.2.3. Regulatory framework
      • 9.4.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.3. Canada
      • 9.4.3.1. Key country dynamics
      • 9.4.3.2. Competitive scenario
      • 9.4.3.3. Regulatory framework
      • 9.4.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.4. Mexico
      • 9.4.4.1. Key country dynamics
      • 9.4.4.2. Competitive scenario
      • 9.4.4.3. Regulatory framework
      • 9.4.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5. Europe
    • 9.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 9.5.2. UK
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Competitive scenario
      • 9.5.2.3. Regulatory framework
      • 9.5.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.3. Germany
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Competitive scenario
      • 9.5.3.3. Regulatory framework
      • 9.5.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.4. France
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Competitive scenario
      • 9.5.4.3. Regulatory framework
      • 9.5.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.5. Italy
      • 9.5.5.1. Key country dynamics
      • 9.5.5.2. Competitive scenario
      • 9.5.5.3. Regulatory framework
      • 9.5.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.6. Spain
      • 9.5.6.1. Key country dynamics
      • 9.5.6.2. Competitive scenario
      • 9.5.6.3. Regulatory framework
      • 9.5.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.7. Denmark
      • 9.5.7.1. Key country dynamics
      • 9.5.7.2. Competitive scenario
      • 9.5.7.3. Regulatory framework
      • 9.5.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.8. Sweden
      • 9.5.8.1. Key country dynamics
      • 9.5.8.2. Competitive scenario
      • 9.5.8.3. Regulatory framework
      • 9.5.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.9. Norway
      • 9.5.9.1. Key country dynamics
      • 9.5.9.2. Competitive scenario
      • 9.5.9.3. Regulatory framework
      • 9.5.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6. Asia Pacific
    • 9.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 9.6.2. Japan
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Competitive scenario
      • 9.6.2.3. Regulatory framework
      • 9.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.3. China
      • 9.6.3.1. Key country dynamics
      • 9.6.3.2. Competitive scenario
      • 9.6.3.3. Regulatory framework
      • 9.6.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.4. India
      • 9.6.4.1. Key country dynamics
      • 9.6.4.2. Competitive scenario
      • 9.6.4.3. Regulatory framework
      • 9.6.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.5. Australia
      • 9.6.5.1. Key country dynamics
      • 9.6.5.2. Competitive scenario
      • 9.6.5.3. Regulatory framework
      • 9.6.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.6. South Korea
      • 9.6.6.1. Key country dynamics
      • 9.6.6.2. Competitive scenario
      • 9.6.6.3. Regulatory framework
      • 9.6.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.7. Thailand
      • 9.6.7.1. Key country dynamics
      • 9.6.7.2. Competitive scenario
      • 9.6.7.3. Regulatory framework
      • 9.6.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7. Latin America
    • 9.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 9.7.2. Brazil
      • 9.7.2.1. Key country dynamics
      • 9.7.2.2. Competitive scenario
      • 9.7.2.3. Regulatory framework
      • 9.7.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.3. Argentina
      • 9.7.3.1. Key country dynamics
      • 9.7.3.2. Competitive scenario
      • 9.7.3.3. Regulatory framework
      • 9.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8. MEA
    • 9.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 9.8.2. South Africa
      • 9.8.2.1. Key country dynamics
      • 9.8.2.2. Competitive scenario
      • 9.8.2.3. Regulatory framework
      • 9.8.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.8.3. Saudi Arabia
      • 9.8.3.1. Key country dynamics
      • 9.8.3.2. Competitive scenario
      • 9.8.3.3. Regulatory framework
      • 9.8.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.8.4. UAE
      • 9.8.4.1. Key country dynamics
      • 9.8.4.2. Competitive scenario
      • 9.8.4.3. Regulatory framework
      • 9.8.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.8.5. Kuwait
      • 9.8.5.1. Key country dynamics
      • 9.8.5.2. Competitive scenario
      • 9.8.5.3. Regulatory framework
      • 9.8.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Company Categorization
  • 10.2. Company Market Position Analysis, 2023
  • 10.3. Company Profiles
    • 10.3.1. Eurofins Scientific
      • 10.3.1.1. Company overview
      • 10.3.1.2. Financial performance
      • 10.3.1.3. Service benchmarking
      • 10.3.1.4. Strategic initiatives
    • 10.3.2. Charles River Laboratories
      • 10.3.2.1. Company overview
      • 10.3.2.2. Financial performance
      • 10.3.2.3. Service benchmarking
      • 10.3.2.4. Strategic initiatives
    • 10.3.3. Wuxi AppTec
      • 10.3.3.1. Company overview
      • 10.3.3.2. Financial performance
      • 10.3.3.3. Service benchmarking
      • 10.3.3.4. Strategic initiatives
    • 10.3.4. SGS Societe Generale de Surveillance SA.
      • 10.3.4.1. Company overview
      • 10.3.4.2. Financial performance
      • 10.3.4.3. Service benchmarking
      • 10.3.4.4. Strategic initiatives
    • 10.3.5. Intertek Group Plc
      • 10.3.5.1. Company overview
      • 10.3.5.2. Financial performance
      • 10.3.5.3. Service benchmarking
      • 10.3.5.4. Strategic initiatives
    • 10.3.6. Almac Group
      • 10.3.6.1. Company overview
      • 10.3.6.2. Financial performance
      • 10.3.6.3. Service benchmarking
      • 10.3.6.4. Strategic initiatives
    • 10.3.7. Cambrex Corporation
      • 10.3.7.1. Company overview
      • 10.3.7.2. Financial performance
      • 10.3.7.3. Service benchmarking
      • 10.3.7.4. Strategic initiatives
    • 10.3.8. Pharmaron
      • 10.3.8.1. Company overview
      • 10.3.8.2. Financial performance
      • 10.3.8.3. Service benchmarking
      • 10.3.8.4. Strategic initiatives
    • 10.3.9. Laboratory Corporation of America Holdings
      • 10.3.9.1. Company overview
      • 10.3.9.2. Financial performance
      • 10.3.9.3. Service benchmarking
      • 10.3.9.4. Strategic initiatives
    • 10.3.10. Syngene International Limited
      • 10.3.10.1. Company overview
      • 10.3.10.2. Financial performance
      • 10.3.10.3. Service benchmarking
      • 10.3.10.4. Strategic initiatives
    • 10.3.11. PCI Pharma Services
      • 10.3.11.1. Company overview
      • 10.3.11.2. Financial performance
      • 10.3.11.3. Service benchmarking
      • 10.3.11.4. Strategic initiatives
    • 10.3.12. Catalent Inc
      • 10.3.12.1. Company overview
      • 10.3.12.2. Financial performance
      • 10.3.12.3. Service benchmarking
      • 10.3.12.4. Strategic initiatives
    • 10.3.13. Symeres
      • 10.3.13.1. Company overview
      • 10.3.13.2. Financial performance
      • 10.3.13.3. Service benchmarking
      • 10.3.13.4. Strategic initiatives
    • 10.3.14. Piramal Pharma Solutions
      • 10.3.14.1. Company overview
      • 10.3.14.2. Financial performance
      • 10.3.14.3. Service benchmarking
      • 10.3.14.4. Strategic initiatives
    • 10.3.15. Frontage Labs
      • 10.3.15.1. Company overview
      • 10.3.15.2. Financial performance
      • 10.3.15.3. Service benchmarking
      • 10.3.15.4. Strategic initiatives
    • 10.3.16. Veeda Clinical Research
      • 10.3.16.1. Company overview
      • 10.3.16.2. Financial performance
      • 10.3.16.3. Service benchmarking
      • 10.3.16.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 4 Global Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 5 Global Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 6 Global Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 7 Global Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 8 Global Pharmaceutical Impurity Synthesis and Isolation Services, by Region, 2018 - 2030 (USD Million)
  • Table 9 North America Pharmaceutical Impurity Synthesis and Isolation Services, by Country, 2018 - 2030 (USD Million)
  • Table 10 North America Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 11 North America Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 12 North America Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 13 North America Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 14 North America Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 15 U.S. Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 16 U.S. Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 17 U.S. Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 18 U.S. Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 19 U.S. Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Canada Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 21 Canada Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 22 Canada Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 23 Canada Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 24 Canada Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 25 Mexico Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 26 Mexico Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 27 Mexico Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 28 Mexico Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 29 Mexico Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 30 UK Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 31 UK Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 32 UK Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 33 UK Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 34 UK Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Germany Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 36 Germany Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 37 Germany Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 38 Germany Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 39 Germany Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 40 France Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 41 France Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 42 France Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 43 France Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 44 France Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Italy Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 46 Italy Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 47 Italy Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 48 Italy Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 49 Italy Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 50 Spain Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 51 Spain Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 52 Spain Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 53 Spain Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 54 Spain Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 55 Sweden Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 56 Sweden Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 57 Sweden Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 58 Sweden Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 59 Sweden Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 60 Norway Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 61 Norway Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 62 Norway Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 63 Norway Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 64 Norway Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 65 Denmark Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 66 Denmark Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 67 Denmark Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 68 Denmark Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 69 Denmark Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 70 India Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 71 India Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 72 India Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 73 India Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 74 India Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 75 China Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 76 China Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 77 China Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 78 China Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 79 China Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 80 Japan Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 81 Japan Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 82 Japan Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 83 Japan Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 84 Japan Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 85 India Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 86 India Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 87 India Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 88 India Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 89 India Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 90 Australia Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 91 Australia Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 92 Australia Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 93 Australia Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 94 Australia Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 95 Thailand Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 96 Thailand Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 97 Thailand Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 98 Thailand Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 99 Thailand Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 100 South Korea Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 101 South Korea Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 102 South Korea Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 103 South Korea Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 104 South Korea Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 105 Brazil Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 106 Brazil Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 107 Brazil Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 108 Brazil Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 109 Brazil Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 110 Argentina Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 111 Argentina Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 112 Argentina Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 113 Argentina Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 114 Argentina Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 117 Saudi Arabia Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 118 Saudi Arabia Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 119 Saudi Arabia Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 120 UAE Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 121 UAE Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 122 UAE Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 123 UAE Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 124 UAE Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 125 Kuwait Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 126 Kuwait Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 127 Kuwait Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 128 Kuwait Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 129 Kuwait Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Pharmaceutical Impurity Synthesis and Isolation Services, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 PESTEL Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Service, 2018 - 2030 (USD Million)
  • Fig. 13 Global Pharmaceutical Impurity Synthesis and Isolation Synthesis Services, for Synthesis Services, 2018 - 2030 (USD Million)
  • Fig. 14 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Isolation Services, 2018 - 2030 (USD Million)
  • Fig. 15 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Analytical Services, 2018 - 2030 (USD Million)
  • Fig. 16 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Organic Impurities, 2018 - 2030 (USD Million)
  • Fig. 17 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Inorganic Impurities, 2018 - 2030 (USD Million)
  • Fig. 18 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Residual Solvents, 2018 - 2030 (USD Million)
  • Fig. 19 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Chromatography, 2018 - 2030 (USD Million)
  • Fig. 20 Global Chromatography Pharmaceutical Impurity Synthesis and Isolation Services, for HPLC, 2018 - 2030 (USD Million)
  • Fig. 21 Global Chromatography Pharmaceutical Impurity Synthesis and Isolation Services, for Gas Chromatography, 2018 - 2030 (USD Million)
  • Fig. 22 Global Chromatography Pharmaceutical Impurity Synthesis and Isolation Services, for Preparative Chromatography, 2018 - 2030 (USD Million)
  • Fig. 23 Global Chromatography Pharmaceutical Impurity Synthesis and Isolation Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 24 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Spectroscopy, 2018 - 2030 (USD Million)
  • Fig. 25 Global Spectroscopy Pharmaceutical Impurity Synthesis and Isolation Services, for Mass Spectroscopy, 2018 - 2030 (USD Million)
  • Fig. 26 Global Spectroscopy Pharmaceutical Impurity Synthesis and Isolation Services, for Nuclear Magnetic Resonance (NMR) Spectroscopy, 2018 - 2030 (USD Million)
  • Fig. 27 Global Spectroscopy Pharmaceutical Impurity Synthesis and Isolation Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 28 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Crystallization, 2018 - 2030 (USD Million)
  • Fig. 29 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Hyphenated Techniques, 2018 - 2030 (USD Million)
  • Fig. 30 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 31 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Drug Development, 2018 - 2030 (USD Million)
  • Fig. 32 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Commercial Manufacturing, 2018 - 2030 (USD Million)
  • Fig. 33 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Quality Control, 2018 - 2030 (USD Million)
  • Fig. 34 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Regulatory Compliance, 2018 - 2030 (USD Million)
  • Fig. 35 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Biotech & Pharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 36 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Contract Research Organizations (CRO), 2018 - 2030 (USD Million)
  • Fig. 37 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 38 Regional Outlook, 2023 & 2030
  • Fig. 39 North America Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 US Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Canada Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Mexico Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Germany Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 France Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Italy Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Spain Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Denmark Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Sweden Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Norway Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Japan Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 China Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 India Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Australia Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 South Korea Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Latin America Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Brazil Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Argentina Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Middle East and Africa Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 South Africa Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Saudi Arabia Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 UAE Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Kuwait Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)